期刊文献+

皮肤血管瘤患儿尿液中碱性成纤维细胞生长因子的检测

Determination of basic fibroblast growth factor (bFGF) level in urine from infants and young children with cutaneous hemangioma
原文传递
导出
摘要 目的 检测尿液中碱性成纤维细胞生长因子(bFGF)水平在血管瘤病程中的变化,为临床监测血管瘤的发生发展提供客观依据.方法 采用酶联免疫吸附法(ELISA)检测27例增生期皮肤血管瘤患儿浅层X线治疗前后尿液中bFGF水平的变化,同时选择30例健康婴幼儿尿液作为对照.结果 增生期血管瘤患儿治疗前尿液中bFGF水平高于治疗后3个月和对照组,差异有统计学意义(t=0.206,P<0.05),治疗后3个月与对照组之间bFGF水平的差异无统计学意义(t=0.505,P>0.05).结论 ELISA检测尿液中bFGF方法简便、可靠,可为临床监测血管瘤发生发展提供客观指标. Objective To determine the changes of urine bFGF level in the progression of cutaneous hemangioma,and to provide an objective index for the monitoring of hemangioma occurrence and development.Methods Enzyme-linked immunosorbent assay (ELISA) was used to determine the bFGF level in urine samples from 27 infants and young children with proliferative cutaneous hemangioma before and after treatment with low-dose superficial X-ray,and from 30 normal control infants and young children.Results The urine bFGF level was significantly higher in the patients before treatment than in those 3 months after the treatment and normal controls(t = 3.793,0.206,both P 〈 0.05),while no significant difference was observed in the urine bFGF level between the treated patients and controls (t = 0.505,P 〉 0.05).Conclusions Measurement of urine bFGF level by ELISA is a convenient and reliable method ,which may provide an objective index for the monitoring of hemangioma occurrence and development.
出处 《国际皮肤性病学杂志》 2011年第4期208-210,共3页 International Journal of Dermatology and Venereology
关键词 血管瘤 成纤维细胞生长因子2 X线疗法 Hemangioma Fibroblast growth factor 2 X-ray therapy
  • 相关文献

参考文献2

二级参考文献14

  • 1North PE, DeAos I, Lal A, et al. High expression of indoleamine. 2,3 deoxygenase in infantile hemangioma: Evidence. for immune tolerance. Mod Pathol, 2004, 17: 97A.
  • 2North PE, Waner M, Mizeracki A, et al. GLUTI: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol, 2000, 31( 1 ): 11-22.
  • 3Bree AF, Siegfried E, Sotelo-Avila C, et al. Infantile hemangiomas: speculation on placental trophoblastic origin. Arch Dermatol, 2001, 137(5): 573-577.
  • 4Enjolras O, Mulliken JB, Boon LM, et at Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg, 2001, 107(7): 1647-1654.
  • 5North PE, Waner M, James CA, et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol, 2001, 137( 12 ): 1607.
  • 6Berenguer B, Mulliken JB, Enjolras O, et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features. Pediatr Dev Pathol, 2003, 6(6): 495-510.
  • 7Dadras SS, North PE, Bertoncini J, et al. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol, 2004, 17(9): 1068-1079.
  • 8Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol, 2004, 28( 5 ): 559.
  • 9North PE, Waner M, Buckmiller L, et al. Vascular tumors of infancy and childhood: beyond capillary hemangioma. Cardiovasc Pathol, 2006, 15(6): 303-317.
  • 10Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions alter Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol, 2000, 42(2 Pt 1 ): 225-235.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部